logo

For the Inventor, By the Inventor

Hoersholm, Denmark

Santaris Pharma A/s


USPTO Granted Patents = 44

% Expired Patents = 72.7



Forward Citations = 1,585

Loading Chart...
Loading Chart...

57 inventors (with patents filed for the assignee):

goldMedal Charlotte Albaek Thrue (11 out of 19 patents)

silverMedal Majken Westergaard (10 out of 17 patents)

bronzeMedal Troels Koch (9 out of 25 patents)

4.  Henrik Frydenlund Hansen (8 out of 32 patents)

5.  Christoph Rosenbohm (7 out of 17 patents)

6.  Jesper Worm (7 out of 10 patents)

7.  Daniel Sejer Pedersen (6 out of 12 patents)

8.  Sakari Kauppinen (6 out of 26 patents)

9.  Signe M Christensen (5 out of 10 patents)

10.  Joacim Elmén (4 out of 10 patents)

11.  Paul E G Kristjansen (4 out of 6 patents)

12.  Jesper Wengel (4 out of 14 patents)

13.  Margit Wissenbach (4 out of 4 patents)

14.  Jens Bo Rode Hansen (4 out of 4 patents)

15.  Frank Winther Rasmussen (3 out of 58 patents)


Core Competencies:
RNA Antagonists
LNA Oligonucleotides
MicroRNA Modulation
HIF-1A Expression
Antisense Oligomers
Leukemia Treatment
Beta-Catenin Expression
Cancer Therapy
Short Interfering RNA
Oligomeric Compounds
PCSK9 Targeting
Androgen Receptor

44 patents:

1. 9045518 - Amino-LNA, thio-LNA and alpha-L-oxy-LN (2015-06-02),
2. 9040493 - RNA antagonists targeting GLI2 for the treatment of leukemia (2015-05-26),
3. 8906871 - MicromiRs (2014-12-09),
4. 8785617 - Oligomeric compounds for the modulation of HIF-1A expression (2014-07-22),
5. RE44779 - Bicyclonucleoside and oligonucleotide analogues (2014-02-24),
6. 8653252 - Short interfering RNA (siRNA) analogues (2014-02-18),
7. 8580756 - Short oligomer antagonist compounds for the modulation of target mRNA (2013-11-12),
8. 8563528 - Antisense oligomers targeting PCSK9 (2013-10-22),
9. 8492390 - Synthesis of locked nucleic acid derivatives (2013-07-23),
10. 8492357 - Micro-RNA mediated modulation of colony stimulating factors (2013-07-23),
11. 8470791 - RNA antagonist compounds for the inhibition of Apo-B100 expression (2013-06-25),
12. 8450291 - RNA antagonist compounds for the modulation of PIK3CA expression (2013-05-28),
13. 8450290 - Methods for treating androgen receptor dependent disorders including cancers (2013-05-28),
14. 8440809 - RNA antagonists targeting Hsp27 (2013-05-14),
15. 8440637 - Combination treatment for the treatment of hepatitis C virus infection (2013-05-14),
Company Overview
Santaris Pharma A/S, based in Hoersholm, Denmark, specializes in the development of innovative RNA-targeted therapeutics. The company focuses on Locked Nucleic Acid (LNA) technology, which enhances the efficacy of oligonucleotide analogues, including RNA antagonists and antisense oligonucleotides. Santaris is dedicated to advancing treatments for cancer by modulating key biological pathways, such as HIF-1A and PIK3CA expression, leveraging its expertise in microRNA and oligonucleotide research to address unmet medical needs.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Santaris Pharma A/s USPTO Patent Assignee Logo
44 Patents

#2 in Hoersholm

#75 in Denmark

#15,756 in the World

Hoersholm, DK
Hoersholm, Denmark

Santaris Pharma A/s

Forward Citations = 1,585

57 inventors:

goldMedal Charlotte Albaek Thrue (11 out of 19 patents)

silverMedal Majken Westergaard (10 out of 17 patents)

bronzeMedal Troels Koch (9 out of 25 patents)

4.  Henrik Frydenlund Hansen (8 out of 32 patents)

5.  Christoph Rosenbohm (7 out of 17 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Santaris Pharma A/s. Retrieved from https://idiyas.com/company/santaris-pharma-a-s

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…